NAD+, NMN & Sirtuins: The Cellular Energy and Longevity Axis

Nicotinamide adenine dinucleotide (NAD+) occupies a position at the intersection of cellular energy metabolism and longevity biology that few molecules can match. It is simultaneously a coenzyme essential for the redox reactions of glycolysis, the TCA cycle, and oxidative phosphorylation — meaning all cells depend on it for energy production — and a critical signaling molecule that activates the sirtuin family of longevity-associated deacylases and regulates the DNA damage response through PARP enzymes. Its decline with aging is one of the most consistent and consequential molecular changes in the aging organism, and its restoration has emerged as one of the most actively investigated strategies in longevity medicine.

Understanding NAD+ biology — how it is made, how it is consumed, why it falls with aging, and how fasting, exercise, and supplementation restore it — provides the mechanistic foundation for one of the most rational and evidence-supported longevity interventions available.

NAD+ Biology: The Fundamentals

What NAD+ Does

NAD+ performs two fundamentally distinct biological roles:

1. Redox coenzyme (energy metabolism): NAD+ accepts electrons during glycolysis and the TCA cycle, becoming NADH. NADH then donates these electrons to Complex I of the mitochondrial electron transport chain, driving the proton gradient that powers ATP synthesis through oxidative phosphorylation. The NAD+/NADH ratio is a primary indicator of cellular redox state and metabolic efficiency. Without adequate NAD+, these fundamental energy-producing reactions cannot proceed at full capacity.

2. Signaling molecule (longevity pathways): NAD+ is consumed (not merely used and regenerated, but actually consumed) as a substrate by three major enzyme families:

• Sirtuins (SIRT1–7): NAD+-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, fat oxidation, inflammation, and stress resistance. Each sirtuin reaction consumes one molecule of NAD+, producing nicotinamide (NAM) as a byproduct.
• PARPs (poly-ADP-ribose polymerases): NAD+-dependent DNA repair enzymes. PARP1, activated by DNA damage, consumes NAD+ at a rapid rate to add ADP-ribose polymers to histones at DNA break sites, recruiting the DNA repair machinery. During periods of elevated DNA damage (which increase with aging), PARP-mediated NAD+ consumption accelerates dramatically.
• CD38: An NAD+ase expressed on immune and other cells that hydrolyzes NAD+ to produce cyclic ADP-ribose (a calcium-signaling molecule). CD38 expression increases dramatically with aging and is a primary driver of NAD+ decline in aged tissues.

The NAD+ Biosynthesis Pathways

The body synthesizes NAD+ through several pathways:

• The salvage pathway (primary in most tissues): Nicotinamide (NAM) — produced as a byproduct of sirtuin and PARP activity — is recycled back to NAD+ through the action of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme of the salvage pathway. NAMPT activity is a primary determinant of intracellular NAD+ levels and declines with aging.
• The Preiss-Handler pathway: Nicotinic acid (niacin/vitamin B3) is converted to NAD+ through a three-step pathway involving NAPRT, NMNAT, and NADSYN enzymes.
• The de novo pathway: Tryptophan is converted to NAD+ through the kynurenine pathway. This pathway is quantitatively minor in most conditions but becomes relevant under conditions of tryptophan loading or when other pathways are compromised.
• The NMN/NR pathway: Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors that enter the salvage pathway at different points. NR is converted to NMN by NRK kinases; NMN is converted to NAD+ by NMNAT enzymes. These are the precursors used in current NAD+ supplementation strategies.

Why NAD+ Falls with Aging

NAD+ levels decline by approximately 50% between young adulthood and middle age, with further decline into old age. The primary drivers of this decline are:

• Increased PARP consumption: Accumulated DNA damage with aging dramatically increases PARP1 activation and the rate of NAD+ consumption for DNA repair
• CD38 upregulation: CD38 expression on immune cells increases with aging and the low-grade inflammation of inflammaging, dramatically increasing NAD+ hydrolysis. CD38-expressing senescent cells are a particularly significant source of CD38-driven NAD+ depletion.
• Declining NAMPT activity: The rate-limiting salvage pathway enzyme declines with aging, reducing the rate of NAM recycling to NAD+
• Mitochondrial dysfunction: Dysfunctional mitochondria are less efficient at regenerating NAD+ from NADH through the electron transport chain, contributing to NAD+ depletion
• Reduced dietary precursor intake: Dietary intake of NAD+ precursors (tryptophan, niacin) may be suboptimal in older adults with reduced dietary variety

Sirtuins: The NAD+-Dependent Longevity Enzymes

The Sirtuin Family

The seven mammalian sirtuins (SIRT1–7) are distributed across cellular compartments and regulate fundamentally different biological processes, but share the requirement for NAD+ as a co-substrate:

• SIRT1 (nucleus/cytoplasm): The most extensively studied sirtuin. Deacetylates and activates PGC-1α (driving mitochondrial biogenesis), FOXO transcription factors (promoting stress resistance and longevity gene expression), p53 (regulating DNA damage response), NF-κB (reducing inflammatory gene expression), and numerous other targets. SIRT1 is a primary mediator of the metabolic effects of fasting and caloric restriction.
• SIRT2 (cytoplasm): Regulates cell cycle progression, microtubule dynamics, and fat metabolism. Implicated in neuroprotection against Parkinson's disease pathology.
• SIRT3 (mitochondria): The primary mitochondrial sirtuin. Deacetylates and activates key mitochondrial metabolic enzymes (PDHA, HMGCS2, SOD2, LCAD), enhancing mitochondrial efficiency, ketone production, fatty acid oxidation, and antioxidant defense. SIRT3 is essential for the metabolic adaptations of fasting and caloric restriction in mitochondria.
• SIRT4 (mitochondria): Regulates glutamine metabolism and insulin secretion; ADP-ribosylates and inhibits GDH (glutamate dehydrogenase) to suppress insulin secretion during fasting.
• SIRT5 (mitochondria): Regulates the urea cycle and detoxification; desuccinylase and demalonylase activity on multiple mitochondrial proteins.
• SIRT6 (nucleus): Critical for DNA double-strand break repair, telomere maintenance, and suppression of inflammatory gene expression. Overexpression of SIRT6 extends lifespan in male mice by 15%. SIRT6 deacetylates histones at DNA damage sites, recruiting repair machinery.
• SIRT7 (nucleolus): Regulates ribosomal DNA transcription, mitochondrial biogenesis, and the integrated stress response.

How Fasting and Caloric Restriction Activate Sirtuins

Fasting and caloric restriction activate sirtuins through two converging mechanisms:

• NAD+ elevation: During fasting, the shift from glucose to fat and ketone metabolism increases the NAD+/NADH ratio — glycolysis produces NADH from NAD+, and when glucose is limited, less NADH is produced, preserving NAD+ availability. Higher NAD+ levels provide more substrate for sirtuin reactions, directly activating sirtuin-dependent processes.
• AMPK-NAMPT axis: AMPK activation during fasting upregulates NAMPT expression, increasing the rate of NAD+ synthesis through the salvage pathway. This AMPK-driven NAMPT upregulation is a primary mechanism through which fasting restores NAD+ levels and activates downstream sirtuin activity.

This NAD+/sirtuin activation is one of the primary molecular mechanisms through which fasting and caloric restriction produce their metabolic, anti-inflammatory, and longevity effects — connecting the cellular energy sensing of fasting directly to the transcriptional programs that regulate stress resistance, mitochondrial function, and DNA repair.

NMN and NR: The NAD+ Precursor Supplements

The Case for NAD+ Precursor Supplementation

If declining NAD+ is a driver of aging — impairing sirtuin function, reducing DNA repair capacity, reducing mitochondrial efficiency, and amplifying inflammaging — then restoring NAD+ levels through precursor supplementation should partially reverse these aging phenotypes. This is the core hypothesis driving NAD+ precursor research, and the evidence in animal models is compelling:

• NMN supplementation in aged mice restores NAD+ levels to those of young mice, improves muscle function, energy metabolism, insulin sensitivity, eye function, bone density, immune function, and in some studies extends lifespan
• NR supplementation in aged mice similarly restores NAD+, improves mitochondrial function, reduces muscle wasting, and improves cognitive function
• In mouse models of specific diseases (heart failure, Alzheimer's disease, ALS, diabetic neuropathy, obesity), NMN or NR supplementation has shown significant protective effects

Human Clinical Evidence

Human clinical data for NAD+ precursors is accumulating but more limited than the animal data:

• NR supplementation (250–2000 mg/day): Consistently raises blood NAD+ levels in human studies (by 40–100% depending on dose). The Elysium Basis trial and multiple independent studies confirm reliable NAD+ elevation with NR. Clinical outcome data beyond biomarker changes is more limited, but studies have shown improvements in muscle NAD+ levels, reductions in inflammatory markers, and improvements in physical function in older adults.
• NMN supplementation (250–1200 mg/day): A landmark 2021 human RCT (Igarashi et al., published in NPJ Aging) showed that NMN supplementation in older adults significantly improved muscle NAD+ levels, increased walking speed, and improved grip strength. Multiple subsequent trials have shown NMN reliably raises blood and tissue NAD+ and improves metabolic markers in older and middle-aged adults.
• Route of administration: Standard oral NMN/NR raises blood NAD+ reliably; whether this translates to intracellular tissue NAD+ elevation is a subject of ongoing research. Sublingual NMN formulations may provide faster absorption and better bioavailability than standard oral forms. IV NAD+ infusions (used in some clinical settings) provide the most direct tissue delivery but are expensive and require clinical administration.

NMN vs. NR: Key Differences

• NMN is one step closer to NAD+ in the biosynthetic pathway (NMN → NAD+ via NMNAT); NR requires an additional phosphorylation step (NR → NMN → NAD+)
• NMN is absorbed directly into cells via the Slc12a8 transporter (demonstrated in mice; human data emerging); NR may be partially converted to NAM in the gut before absorption and reconverted intracellularly
• NR has a more established human clinical literature and was commercially available earlier; NMN is catching up rapidly and the 2021 Igarashi RCT provides direct human muscle NAD+ and functional evidence
• Both raise blood NAD+ reliably; tissue-specific differences are an active research area. Many longevity practitioners use both or alternate between them.

Dosing and Timing

• NMN: 250–500 mg/day as a standard dose; 500–1000 mg/day for more aggressive supplementation. Morning dosing is commonly recommended, potentially timed with or before the eating window to align with the circadian peak of NAMPT activity.
• NR: 300–500 mg/day standard; some protocols use up to 1000 mg/day. Available in standard capsule and some sublingual forms.
• Cycling: Some longevity practitioners cycle NAD+ precursors (5 days on, 2 days off, or monthly cycles) rather than continuous dosing, to prevent potential feedback downregulation of endogenous NAD+ synthesis pathways — though the clinical evidence for or against cycling is not yet definitive.

Synergistic NAD+ Stack

NAD+ precursor effectiveness is substantially enhanced by addressing the consumption side of the NAD+ equation — reducing the enzymatic drains that deplete NAD+ — alongside increasing its production:

• CD38 inhibition: Apigenin (a flavonoid found in parsley, chamomile, celery) and luteolin are natural CD38 inhibitors that reduce the primary age-related NAD+ drain. Apigenin (50–100 mg/day) combined with NMN/NR addresses both supply and consumption.
• PARP inhibition: Reducing DNA damage (through antioxidants, DNA repair support, and lifestyle factors that minimize genotoxic stress) reduces PARP-mediated NAD+ consumption. NAD+ precursor supplementation works better when PARP demand is reduced.
• Resveratrol and pterostilbene: SIRT1 activators (STACs — sirtuin-activating compounds) that enhance SIRT1 activity independent of NAD+ levels, amplifying the downstream effects of NAD+ restoration. Pterostilbene (a methylated resveratrol analog with superior bioavailability) at 50–100 mg/day is the preferred form.
• Fasting: As discussed, fasting raises the NAD+/NADH ratio and upregulates NAMPT through AMPK — the most physiologically grounded NAD+ restoration strategy, complementing supplemental precursor approaches.
• Exercise: Resistance and aerobic exercise activate AMPK and upregulate NAMPT, raising skeletal muscle NAD+ and activating SIRT1 and SIRT3 in muscle — the most important tissue site for metabolic NAD+ biology.

Fasting, NAD+, and Sirtuins: The Integration

The convergence of fasting and NAD+/sirtuin biology produces a set of integrated effects that are greater than either intervention alone:

• Fasting raises NAD+ → activates SIRT1 → deacetylates PGC-1α → drives mitochondrial biogenesis and fat oxidation
• Fasting raises NAD+ → activates SIRT3 → deacetylates mitochondrial metabolic enzymes → enhances ketone production (HMGCS2), fatty acid oxidation (LCAD), and antioxidant defense (SOD2)
• Fasting raises NAD+ → activates SIRT6 → enhances DNA double-strand break repair and telomere maintenance
• Fasting raises NAD+ → activates SIRT1 → deacetylates FOXO3a → upregulates autophagy genes, stress resistance proteins, and antioxidant enzymes
• Fasting raises NAD+ → activates SIRT1 → deacetylates NF-κB → reduces inflammatory gene expression and SASP

NMN or NR supplementation amplifies these fasting-induced sirtuin effects by ensuring NAD+ availability is not the limiting factor during and after fasting cycles — particularly relevant in older adults where baseline NAD+ is already substantially depleted and fasting-induced NAD+ elevation may be blunted by the same NAMPT decline and CD38 upregulation that drive the age-related NAD+ deficit.

Practical Implementation

The Evidence-Based NAD+ Longevity Stack

• NMN 500 mg/day (or NR 500 mg/day, or alternate monthly) — morning, with or without food
• Pterostilbene 50–100 mg/day — SIRT1 activator, taken with NMN/NR
• Apigenin 50–100 mg/day — CD38 inhibitor, reducing NAD+ hydrolysis
• TMG (trimethylglycine) 500–1000 mg/day — methyl donor; NMN supplementation can deplete methyl groups through the methyl cycle; TMG replenishes them
• Fasting protocol: 16:8 daily baseline; quarterly extended fast or FMD for deep NAD+ reset through AMPK-NAMPT upregulation
• Exercise: 3–5 sessions/week (mix of aerobic and resistance) for AMPK-driven NAMPT upregulation and muscle NAD+ restoration

Monitoring

• Intracellular NAD+ testing is now available through specialized labs (Jinfiniti Precision Medicine offers the Intracellular NAD+ Test from a blood draw) — useful for establishing baseline and confirming supplementation efficacy
• Functional markers responsive to NAD+ restoration: energy levels, sleep quality, exercise recovery, cognitive sharpness, and skin quality (all SIRT1/3/6-dependent processes)
• Inflammatory markers (hsCRP, IL-6) should improve with sustained NAD+/sirtuin restoration through SIRT1-mediated NF-κB suppression

Safety Considerations

• NMN and NR have favorable safety profiles in human trials at doses up to 1200 mg/day (NMN) and 2000 mg/day (NR); no serious adverse events have been reported in clinical trials
• High-dose niacin (not NMN/NR) causes flushing through prostaglandin-mediated vasodilation; NMN and NR do not typically cause niacin flush at standard doses
• Theoretical concern: NAD+ precursors raise NAD+ in all cells, including potentially cancer cells (which also upregulate NAMPT). This concern is unresolved in the human literature; individuals with active cancer should discuss NAD+ supplementation with their oncologist
• TMG supplementation can raise homocysteine in some individuals with MTHFR polymorphisms — monitor homocysteine if using TMG
• Drug interactions: NR may interact with medications metabolized by CYP enzymes; consult your physician if on multiple prescription medications

Summary

NAD+ is the molecular hub connecting cellular energy production, DNA repair, inflammatory regulation, mitochondrial function, and the sirtuin longevity pathways — and its age-related decline is one of the most mechanistically consequential molecular changes in aging biology. The convergence of fasting (which raises the NAD+/NADH ratio and upregulates NAMPT), exercise (which activates AMPK-driven NAMPT upregulation in muscle), and NAD+ precursor supplementation (NMN or NR, with CD38 inhibition and SIRT1 activation) represents the most comprehensive available approach to restoring the NAD+ axis that declines with aging.

The sirtuin enzymes that NAD+ activates — SIRT1 driving mitochondrial biogenesis and anti-inflammatory gene expression, SIRT3 optimizing mitochondrial metabolism, SIRT6 maintaining DNA integrity — are among the most validated longevity-associated molecular targets identified in aging biology. Supporting their activity through the three-pronged approach of fasting, exercise, and NAD+ precursor supplementation is one of the most evidence-grounded longevity strategies available to anyone committed to aging well at the cellular level.

This article is for educational purposes only and does not constitute medical advice. Individuals with cancer, on prescription medications, or with metabolic conditions should consult their physician before initiating NAD+ precursor supplementation. NAD+ precursor supplements are not FDA-evaluated for the treatment or prevention of any disease.